Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Neuro Research Center

Neither a doctor nor a teaching hospital

Research payments

$600,878

22 payments

Through program year 2025, Advanced Neuro Research Center is reported as receiving $600,878 in research payments, across 22 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $5,117 2
2024 Research $4,297 6
2023 Research $319,905 7
2022 Research $271,558 7

Breakdown

Who paid Research payments · program years 2022–2025
  1. Eli Lilly and Company $600,878 22 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $198,286 2 payments
  2. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $174,115 3 payments
  3. Obstructive Sleep Apnea Master Protocol Gpif A Study of Tirzepatide (Ly3298176) in Participants With Obstructive Sleep Apnea $58,725 2 payments
  4. Obstructive Sleep Apnea Master Protocol Gpif: A Study of Tirzepatide (Ly3298176) in Participants With Obstructive Sleep Apnea (Surmount-Osa) $58,092 2 payments
  5. Obstructive Sleep Apnea Master Protocol Gpif: A Study of Tirzepatide (Ly3298176) in Participants With Obstructive Sleep Apnea $43,151 2 payments
  6. Obstructive Sleep Apnea Master Protocol Gpif A Study of Tirzepatide (Ly3298176) in Participants With Obstructive Sleep Apnea $35,928 4 payments
  7. Obstructive Sleep Apnea Master Protocol Gpif: A Study of Tirzepatide (Ly3298176) in Participants With Obstructive Sleep Apnea (Surmount-Osa) $22,638 3 payments
  8. Obstructive Sleep Apnea Master Protocol Gpif: A Study of Tirzepatide (Ly3298176) in Participants With Obstructive Sleep Apnea $4,803 1 payment
  9. An Adaptive Phase 2A/2B, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of Ly3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis $4,278 2 payments
  10. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $863 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record